CoronaryAtlas logo
CoronaryAtlas
TES
Pathway / Off-pathway / systemic markers

TES

TESgene

TES, associated with immune deficiency, contributes to myocardial infarction risk through systemic immune dysregulation separate from the atherothrombotic cascade.

Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencelow
RationaleLinked to immune deficiency and MI pathology; off-cascade.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
75
C — confounder / Type-II
76
A — assay feasibility
52
E — evidence strength
31
T1DI (composite)
8
Specificity differential (R−C)-0.7
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Whole blood — gene is not a circulating analyte; measure protein product or genotype
Collection tube
K2-EDTA whole blood (lavender-top)
Method / principle
SNP genotyping / sequencing; or immunoassay of encoded protein
Reagent / substrate
Allele-specific primers/probes (TaqMan) or NGS panel; or antibody for protein
Platform
qPCR / NGS / array
Turnaround · availability
Send-out · Genotyping widely available; protein assay variable

Literature evidence(1)